서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Subject

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 14 of 14

Issue DateTitle / Author(s) / CitationFileAltmetrics
2011-01
Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01)
DOI
2011-09
What is the optimal dose of escitalopram for the treatment of obsessive-compulsive disorder? A naturalistic open-label study

Shim, Geumsook; Park, Hye Youn; Jang, Joon Hwan; Kim, Euitae; Park, Hye Yoon; Hwang, Jae Yeon; Kim, Sung Nyun; Jang, Go-Eun; Kwon, Jun Soo

International Clinical Psychopharmacology, Vol.26 No.5, pp.284-290

DOI
2013-12
Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer
DOI
2014-08
Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: Randomized phase II multicenter trial
DOI
2015-10
Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer
DOI
2016-11
TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials
DOI
2017-04
Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of lmatinib and Sunitinib: A Multicenter Study Based on the Management Access Program
DOI
2018-03
A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma
DOI
2018-11
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3
DOI
2019-05
Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer: Results from the phase III, randomized PALOMA-2 study
DOI
2019-12
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): A multicentre, open-label, randomised, phase 2 trial
DOI
2020-03
Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies
DOI
2020-09
KrAsG12C inhibition with Sotorasib in Advanced Solid Tumors
DOI
2021-02
Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
DOI
1